|
| 37957132 | A Nomogram to Predict Severe Toxicity in DPYD Wild-Type Patients Treated With Capecitabine-Based Anticancer Regimens. | Clin Pharmacol Ther | 2024 |
| 36352517 | Response to "Plasma Uracil as a DPD Phenotyping Test: Pre-analytical Handling Matters". | Clin Pharmacol Ther | 2023 |
| 37639651 | Survival of Patients With Cancer With <i>DPYD</i> Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair Analysis. | J Clin Oncol | 2023 |
| 37059834 | Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. | Nat Med | 2023 |
| 32800401 | Systemic exposure of oxaliplatin and docetaxel in gastric cancer patients with peritonitis carcinomatosis treated with intraperitoneal hyperthermic chemotherapy. | Eur J Surg Oncol | 2021 |
| 33484280 | Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors. | Cancer Chemother Pharmacol | 2021 |
| 33710154 | Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial. | Otol Neurotol | 2021 |
| 34132450 | A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors. | Oncologist | 2021 |
| 33170484 | Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors. | Target Oncol | 2021 |
| 33211315 | Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial. | Target Oncol | 2021 |
| 33296125 | Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer. | Oncologist | 2021 |
| 33262140 | Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung Cancer. | Clin Cancer Res | 2021 |
| 33230210 | A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours. | Br J Cancer | 2021 |
| 31065954 | A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma. | Invest New Drugs | 2020 |
| 31907288 | Circulating epithelial tumor cell analysis in CSF in patients with leptomeningeal metastases. | Neurology | 2020 |
| 31870883 | Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. | J Thorac Oncol | 2020 |
| 31667659 | Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1). | Invest New Drugs | 2020 |
| 31838077 | Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis. | Pharmacol Res | 2020 |
| 31637669 | Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). | Invest New Drugs | 2020 |
| 32047001 | <i>BRAF</i>-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. | Clin Cancer Res | 2020 |
| 32006223 | Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors. | Clin Pharmacokinet | 2020 |
| 32818466 | Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. | Lancet Oncol | 2020 |
| 32725720 | No relation between docetaxel administration route and high-grade diarrhea incidence. | Pharmacol Res Perspect | 2020 |
| 32524189 | Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. | Cancer Chemother Pharmacol | 2020 |
| 32179633 | A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors. | J Immunother Cancer | 2020 |
| 32147669 | Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer. | Br J Cancer | 2020 |
| 32562841 | Breakthrough therapy-designated oncology drugs: are they rightfully criticized? | Drug Discov Today | 2020 |
| 32320048 | Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. | Cancer | 2020 |
| 32227355 | Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment. | Br J Clin Pharmacol | 2020 |
| 31215049 | Bioanalytical LC-MS/MS validation of therapeutic drug monitoring assays in oncology. | Biomed Chromatogr | 2020 |
| 31595980 | A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development. | J Clin Pharmacol | 2020 |
| 30530116 | Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling. | J Chromatogr B Analyt Technol Biomed Life Sci | 2019 |
| 35100734 | Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations. | JCO Precis Oncol | 2019 |
| 29862467 | Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology. | Clin Pharmacokinet | 2019 |
| 31407460 | Multiparameter Flow Cytometry Assay for Quantification of Immune Cell Subsets, PD-1 Expression Levels and PD-1 Receptor Occupancy by Nivolumab and Pembrolizumab. | Cytometry A | 2019 |
| 30712800 | DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how? - Authors' reply. | Lancet Oncol | 2019 |
| 30892987 | Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. | J Clin Oncol | 2019 |
| 30802002 | Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort. | Cancer Med | 2019 |
| 30734241 | Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice. | Drugs Aging | 2019 |
| 30754019 | Development and validation of LC-MS/MS methods for the quantification of the novel anticancer agent guadecitabine and its active metabolite β⿿decitabine in human plasma, whole blood and urine. | J Chromatogr B Analyt Technol Biomed Life Sci | 2019 |
| 30608567 | Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. | Ann Oncol | 2019 |
| 30485432 | Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis. | Int J Cancer | 2019 |
| 30368118 | Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid. | J Pharm Biomed Anal | 2019 |
| 30366147 | Development, validation, and clinical application of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of total intracellular β-decitabine nucleotides and genomic DNA incorporated β-decitabine and 5-methyl-2'-deoxycytidine. | J Pharm Biomed Anal | 2019 |
| 30617624 | Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study. | Pharm Res | 2019 |
| 30279580 | Impact of age on exposure to oral antiandrogen therapies in clinical practice. | Prostate Cancer Prostatic Dis | 2019 |
| 30585255 | A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours. | Br J Cancer | 2019 |
| 28929491 | Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency. | Int J Cancer | 2018 |
| 29974200 | Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of <sup>14</sup>C-plitidepsin. | Cancer Chemother Pharmacol | 2018 |
| 29911074 | Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis. | Front Cell Infect Microbiol | 2018 |